Jan 12, 2021 7:00am EST Lexaria Bioscience Corp. Announces Uplisting to Nasdaq Capital Market and Pricing of $9.6 Million Upsized Public Offering
Dec 22, 2020 6:30am EST Lexaria Expands COVID-19 Drug Research Program Utilizing Proprietary DehydraTECH
Dec 07, 2020 6:45am EST Lexaria to Highlight its DehydraTECHTM Technology at Four Upcoming Investor Conferences
Dec 01, 2020 6:30am EST Lexaria’s Patented Technology Significantly Enhances Oral Delivery of Antiviral Drugs
Oct 22, 2020 6:15am EDT Lexaria Proprietary DehydraTECH-Enabled CBD Powders Business Growing Faster than Expected